Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReckitt Regulatory News (RKT)

Share Price Information for Reckitt (RKT)

Share Price is delayed by 15 minutes
Get Live Data
4,585.00    45.00 (0.99%)
Bid:
4,593.00
Ask:
4,595.00
Spread: 2.00 (0.044%)
Market Cap: £29.16b
RKT Live PriceLast checked at - London Stock Exchange

Intraday Reckitt Share Chart

2024 SHARE BUYBACK PROGRAMME - SECOND TRANCHE

24 Sep 2024 08:00

RNS Number : 3966F
Reckitt Benckiser Group PLC
24 September 2024
 

RECKITT BENCKISER GROUP PLC

 

2024 SHARE BUYBACK PROGRAMME - SECOND TRANCHE

 

On 24 July 2024, Reckitt Benckiser Group plc ("Reckitt" or the "Company") announced its 2024 £1 billion share buyback programme (the "Programme"). On 26 July 2024, the Company announced commencement of the first tranche of this Programme to return up to £250 million of capital to shareholders (the "First Tranche").

Reckitt today announces its intention to commence the second tranche of the Programme (the "Second Tranche") which will return a further up to £250 million of capital to shareholders, and which will commence on the day following completion of the First Tranche (anticipated to be during September or October 2024).

Reckitt announces that, in connection with the Second Tranche, it has entered into an agreement with Numis Securities Limited ("DN") under which it has issued an instruction to DN to manage the Second Tranche of the Programme. DN will, acting as riskless principal, purchase Ordinary Shares for an aggregate purchase price of no greater than £250 million and will simultaneously sell such Ordinary Shares on to the Company.

Any purchase of Ordinary Shares in relation to this announcement will be carried out on the London Stock Exchange and Multilateral Trading Facilities, as defined by the Directive 2014/65/EU on markets in financial instruments (including the delegated and implementing acts adopted under it) as implemented, retained, amended, extended, re-enacted or otherwise given effect in the United Kingdom from 1 January 2021 and as amended or supplemented in the United Kingdom thereafter, and executed in accordance with the Listing Rules and Reckitt's general authority to make market purchases of Ordinary Shares. The shares will be purchased in accordance with the price and volume conditions set out in the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buyback programmes and stabilisation measures as implemented, retained, amended, extended, re-enacted or otherwise given effect in the United Kingdom from 1 January 2021 and as amended or supplemented in the United Kingdom thereafter.

Reckitt will issue a further announcement upon the commencement of the Second Tranche and will announce any market repurchase of Ordinary Shares no later than 7.30 a.m. on the business day following the calendar day on which the repurchase occurred. To the extent permitted by law, Ordinary Shares purchased under the Second Tranche of the Programme will be held in treasury. For the avoidance of doubt, no repurchases will be made in respect of the Company's American Depository Receipts.

Any further tranches of the Programme, which may be conducted after completion of the Second Tranche, will be announced in due course.

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

CONTACT DETAILS:

Richard Joyce +44 (0)7807 418516

Investor Relations

 

Catheryn O'Rourke +44 (0) 1753 217 800

General Counsel & Company Secretary

 

 About Reckitt:

 

Reckitt* exists to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. We believe that access to the highest-quality hygiene, wellness and nourishment is a right, not a privilege.

Reckitt is the company behind some of the world's most recognisable and trusted consumer brands in hygiene, health and nutrition, including Air Wick, Calgon, Cillit Bang, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, Woolite and more.

Every day, more than 20 million Reckitt products are bought globally. We always put consumers and people first, seek out new opportunities, strive for excellence in all that we do and build shared success with all our partners. We aim to do the right thing, always.

We are a diverse global team of c. 40,000 colleagues. We draw on our collective energy to meet our ambitions of purpose-led brands, a healthier planet and a fairer society. Find out more, or get in touch with us at www.reckitt.com

* Reckitt is the trading name of the Reckitt Benckiser group of companies

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSEZLBLZKLZBBF
Date   Source Headline
7th Sep 202212:00 pmRNSDirector/PDMR Shareholding
1st Sep 202210:55 amRNSTotal Voting Rights
1st Sep 20227:00 amRNSDirectorate Change
11th Aug 202210:27 amRNSDirectorate Change
5th Aug 202212:07 pmRNSDirector Declaration
1st Aug 20224:07 pmRNSTotal Voting Rights
27th Jul 20227:00 amRNSHalf-year Results
19th Jul 20229:41 amRNSDirector Declaration
1st Jul 20221:34 pmRNSTotal Voting Rights
13th Jun 202211:45 amRNSDirector/PDMR Shareholding
1st Jun 202212:37 pmRNSTotal Voting Rights
23rd May 20225:28 pmRNSDirector/PDMR Shareholding
20th May 20225:30 pmRNSResult of AGM
3rd May 202212:54 pmRNSTotal Voting Rights
29th Apr 20227:00 amRNS1st Quarter Results
27th Apr 20224:29 pmRNSNotice of AGM
14th Apr 202212:26 pmRNSAnnual Financial Report
1st Apr 20221:57 pmRNSTotal Voting Rights
22nd Mar 202212:18 pmRNSDirector/PDMR Shareholding
1st Mar 20223:39 pmRNSTotal Voting Rights
17th Feb 20227:00 amRNSReckitt FY 2021 Results
1st Feb 202210:32 amRNSTotal Voting Rights
17th Jan 20229:00 amRNSDirectorate Change
4th Jan 202211:21 amRNSTotal Voting Rights
24th Dec 20217:00 amRNSProposed Sale of E45 to Karo Pharma
1st Dec 202111:22 amRNSTotal Voting Rights
1st Nov 202111:47 amRNSTotal Voting Rights
26th Oct 202110:01 amRNSDirectorate Change
26th Oct 20217:00 amRNS3rd Quarter Results
4th Oct 20219:35 amRNSDirectorate Change
1st Oct 202111:15 amRNSTotal Voting Rights
23rd Sep 20217:00 amRNSTrading Update & Launch of Investor Seminar Series
16th Sep 20211:20 pmRNSDirector/PDMR Shareholding
9th Sep 20219:24 amRNSClosing sale of IFCN China business to Primavera
1st Sep 202111:08 amRNSTotal Voting Rights
31st Aug 20214:00 pmRNSDirector/PDMR Shareholding
4th Aug 202110:30 amRNSDirector/PDMR Shareholding
3rd Aug 20211:30 pmRNSDirector/PDMR Shareholding
2nd Aug 202112:50 pmRNSTotal Voting Rights
30th Jul 202110:57 amRNSDirector Declaration
29th Jul 20213:30 pmRNSDirector/PDMR Shareholding
28th Jul 20214:00 pmRNSDirector/PDMR Shareholding
28th Jul 202110:00 amRNSDirector/PDMR Shareholding
27th Jul 20217:00 amRNSHalf-Year Report
1st Jul 202111:23 amRNSTotal Voting Rights
25th Jun 20212:45 pmRNSDirector Declaration
23rd Jun 20214:25 pmRNSDirector/PDMR Shareholding
17th Jun 202111:31 amRNSDirector/PDMR Shareholding
7th Jun 20217:00 amRNSReckitt to sell IFCN China for US $2.2billion
1st Jun 20212:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.